Newsfeeds - Spark Newswire

6 minute read

Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know

Today, 2:03 PM

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

APLS

2 minute read

$1.8 Million Bet On MacroGenics? Check Out These 3 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 2:03 PM

The Dow Jones traded higher by over 400 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BDTX

5 minute read

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday

By Lisa Levin

Today, 2:03 PM

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

ALF

1 minute read

HC Wainwright & Co. Maintains Buy on Macrogenics, Raises Price Target to $11

By Benzinga Newsdesk

Today, 2:03 PM

HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $10 to $11.

MGNX

2 minute read

Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies; Gilead Will Pay Macrogenics An Upfront Payment Of $60M And MacroGenics Will Be Eligible To Receive Up To $1.7B In Potential Milestones

By Benzinga Newsdesk

Today, 2:03 PM

Gilead Sciences, Inc. (NASDAQ:GILD) and MacroGenics (NASDAQ:MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using

GILD

1 minute read

HC Wainwright & Co. Maintains Buy on Macrogenics, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 2:03 PM

HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $35 to $10.

MGNX

1 minute read

Citigroup Maintains Buy on Macrogenics, Raises Price Target to $16

By Benzinga Newsdesk

Today, 2:03 PM

Citigroup analyst Yigal Nochomovitz maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $13 to $16.

MGNX

1 minute read

Earnings

Earnings Preview: Macrogenics

By Benzinga Insights

Today, 2:03 PM

Macrogenics (NASDAQ:MGNX) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Macrogenics will report an earnings per share (EPS) of $-0.97.

MGNX

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 2:03 PM

Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.

AHCO

7 minute read

This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:03 PM

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.

AMPS